In our study, we found that genetic mutations and deletions in FDX1 might decrease MHC class I (MHC_I) levels, which affects how well peptides bind to MHC molecules and how well endogenous antigens are presented to CD8+ T cells, resulting in cytotoxic T lymphocytes failing to recognize and kill tumor cells. Here, FDX1 is linked to neoplasm.